Biogen Inc said on Monday it has agreed to buy an early-stage experimental treatment from Pfizer Inc that it aims to test in patients with Alzheimer’s and Parkinson’s disease. Under the deal, Pfizer will get $75 million upfront and will be eligible for $635 million in potential milestone payments.